UCB: Pipeline, Products, Performance, Potential

Table of Contents

• Latest Results
• EXECUTIVE SUMMARY
  • Introduction
  • Current Financial Position
    • Company Performance
    • Business Segment Performance
    • Geographic Segment Performance
  • Company Strategy
    • R&D Strategy
    • Mergers, Acquisitions and Divestitures
      • Acquisitions
      • Divestitures
    • Key Agreements
    • Production
  • Product Performance Forecasts
  • Pipeline Analysis
    • Discontinued R&D projects
  • Conclusions/Outlook
• THERAPEUTIC AREA FOCUS
• R&D PIPELINE
• CENTRAL NERVOUS SYSTEM
  • Marketed Products
    • Keppra
    • Metadate CD/Equasym XL
    • Neupro
    • Vimpat
    • Others
  • R&D Projects
    • Rikelta
  • Growth Forecast
• IMMUNO-ALLERGOLOGY
  • Marketed Products
    • Cimzia
    • Xyzal/Xusal
    • Zyrtec/Reactine
    • Others
  • R&D Projects
    • CPD6038
    • Epratuzumab
  • Growth Forecast
• OTHERS
  • Marketed Products
    • Tussionex
    • Others
  • R&D Projects
    • CDP7851
• APPENDIX 1 - FINANCIAL PERFORMANCE
  • Full Year Results 2008
• APPENDIX 2 - KEY CORPORATE EVENTS
• APPENDIX 3 - KEY AGREEMENTS
  • Actelion Ltd.
  • Alembic Limited
  • Amgen
  • AstraZeneca
  • Azur Pharma Inc.
  • Biogen Idec Inc.
  • BioInvent International AB
  • BioWa Inc.
  • Immunomedics Inc.
  • Lonza Biologics Ltd.
  • Merck & Co
  • Nektar Therapeutics
  • Novartis
  • Orphan Medical Inc.
  • Otsuka
  • Pfizer
  • sanofi-aventis
  • Sepracor Inc
  • Teva Pharmaceutical Industries Inc.
  • Verus Pharmaceuticals Inc.
  • Wilex AG
• APPENDIX 4 - INFRASTRUCTURE
  • Research and Development Facilities
  • Manufacturing Facilities
• APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES
  • Subsidiaries
  • Joint Ventures
• APPENDIX 6 - PRODUCT INDEX

INDEX OF TABLES

• Principal Operating Results
• Royalty Income
• Net Pharmaceutical Sales By Geographical Area
• Net Sales By Geographical Area, 2008
• Recent Product Approvals
• Sales Of Major Biopharmaceutical Products
• Major CNS Products, 2008
• Major Immuno-allergology Products, 2008
• Major Other Products, 2008

INDEX OF CHARTS

• Royalty Income, 2008
• Sales of Top Ten Products (2003A-2013E)
• Top Selling Products, 2008
• Keppra Sales (2003A-2013E)
• Metadate Sales (2004A-2013E)
• Neupro Sales (2006A-2013E)
• Vimpat Sales (2009E-2013E)
• Bivaracetam Sales (2010E-2014E)
• Cimzia Sales (2008A-2013E)
• Xyzal Sales (2004A-2013E)
• Zyrtec Sales (2003A-2013E)
• Epratuzumab Sales (2010E-2014E)
• Tussionex Sales (2004A-2013E)
• Sales, Costs and Operating Income
• Profitability and Research Ratios
• R&D Expenditure and Capital Expenditure
• Current Assets, Liabilities and Ratio
• Assets, Cash and Liquidity
• Employees and Productivity